Loader

Pathways

PathWhiz ID Pathway Meta Data

PW091342

Pw091342 View Pathway
disease

TSP-1 Induced Apoptosis in Microvascular Endothelial Cell

Homo sapiens
The members of the large family of matricellular proteins including thrombospondin-1 (TSP1) play important roles in genesis and remodeling of multiple tissues including cartilage and vasculature. TSP1 is one of the important pivots that regulate vascular tissue homeostasis whereas its key function is the negative control of angiogenesis. TSP1 was the first naturally occurring protein inhibitor of angiogenesis to be identified; its anti-angiogenic effects have since been established in a multitude of experimental models and linked to specific epitopes in the multi-domain, multi-functional TSP1 molecule. TSP1 is the first identified, and therefore best studied thrombospondin family representative, its structure is thus considered as prototype for the other family members. In the thrombospondin family, another member, TSP2 has a similar domain structure and, non-surprisingly, its functions significantly overlap with those of TSP1. Specifically, both TSP1 and TSP2 potently inhibit angiogenesis.

PW124299

Pw124299 View Pathway
signaling

TTP

Homo sapiens
TTP

PW124298

Pw124298 View Pathway
signaling

TTP

Homo sapiens
TTP

PW001990

Pw001990 View Pathway
drug action

ttttt

Homo sapiens

PW145286

Pw145286 View Pathway
drug action

Tubocurarine Drug Metabolism Action Pathway

Homo sapiens

PW132546

Pw132546 View Pathway
metabolic

Tucatinib Drug Metabolism

Homo sapiens
Tucatinib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Tucatinib passes through the liver and is then excreted from the body mainly through the kidney.

PW146420

Pw146420 View Pathway
drug action

Tucatinib Drug Metabolism Action Pathway

Homo sapiens

PW128379

Pw128379 View Pathway
drug action

Turoctocog Alfa Action Pathway

Homo sapiens
Turoctocog alfa is a recombinant factor VIII, also known as Novoeight and Zonovate, used to treat bleeding in patients with haemophilia A which is a congenital factor VIII deficiency. It is administered intravenously and acts similarly to coagulation factor VIII, forming a complex with IX in order to activate factor X leading to a blood clot forming. Turoctocog alfa allows the missing factor coagulation VIII to be replaced and restore blood clotting.

PW128461

Pw128461 View Pathway
drug action

Turoctocog Alfa Pegol Action Pathway

Homo sapiens
Turoctocog alfa pegol is a version of turoctocog alfa also known as esperoct, used to treat hemophilia A. The difference between turoctocog alfa pegol and turoctocog alfa is the modification to the structure of turoctocog alfa pegol extends its half-life. It acts by replacing coagulation factor VIII which is deficient in patients with hemophilia.

PW146244

Pw146244 View Pathway
drug action

Turpentine Drug Metabolism Action Pathway

Homo sapiens